Ameliorative effect of atorvastatin on hepatic fibrosis and its mechanism

doi:10.3969/j.issn.1674-8115.2021.12.011

Abstract

Abstract: Objective

·To investigate the role of atorvastatin and its mechanisms in patients and animal models of hepatic fibrosis.

Methods

·The literatures in PubMed were searched for statins for different chronic liver diseases from January 2010 to June 2020. Meta analysis was performed based on the occurrence of liver fibrosis, liver failure and overall patient mortality. Sixteen male C57BL/6 mice were randomly divided into control group, atorvastatin group, CCl₄ injection group, and CCl₄ injection combined with atorvastatin group with 4 mice in each group. The mice in the CCl₄ injection group were administered intraperitoneally twice a week with 20% volume fraction of CCl₄ at a dose of 1 mL/kg; the control group was administered intraperitoneally by using the same dose of corn oil; the mice in the atorvastatin group were gavaged once daily with a dose of 15 mg/kg of atorvastatin; the mice in the CCl₄ injection combined with atorvastatin group were treated with a combination of CCl₄ and atorvastatin. After 4 weeks, the animals were euthanized, and serum glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) were detected; the degree of intrahepatic fibrosis in the mice was detected by Sirius red staining; immunofluorescence staining was used to detect the expression of collagen ⅠA; the mRNA expressions of α-smooth muscle actin (α-SMA), collagen Ⅰ, collagen Ⅲ, interleukin (IL)-1b, IL-6, and transforming growth factor-β (TGF-β) were detected by real-time fluorescence quantitative PCR; the expressions of α-SMA protein and phosphorylated Smad4 (pSmad4) protein were detected by Western blotting.

Results

·Finally 9 papers were selected for meta analysis, and the results showed that statins reduced the incidence of liver fibrosis, liver failure and overall mortality in patients with liver disease. In the animal experiments, the weight of mice in both the CCl₄ injection group and the CCl₄ injection combined with atorvastatin group decreased significantly compared with that in the control group (P=0.000); while the weight of mice in the CCl₄ injection combined with atorvastatin group decreased to a lesser extent compared with that in the CCl₄ injection group (P=0.040). Compared with the control group, GPT and GOT concentrations were significantly increased in both the CCl₄ injection group and CCl₄ injection combined with atorvastatin group (P=0.000), while liver enzymes in the CCl₄ injection combined with atorvastatin group showed a smaller increase in GPT and GOT compared with that in the CCl₄ injection group (P=0.020). Sirius red staining showed excessive deposition of intrahepatic fibers in the CCl₄injection group, and immunostaining suggested high expression of collagen ⅠA in the CCl₄injection group. The results of fluorescence quantitative PCR and Western blotting suggested that α-SMA protein expression increased, and mRNA expressions of α-SMA, collagen Ⅰ, and collagen Ⅲ were upregulated in the CCl₄ injection group compared with the control group(P<0.05), whereas the expressions of these markers were downregulated in the CCl₄ injection combined with atorvastatin group compared with the CCl₄ injection group (P<0.05). The mRNA expressions of IL-1b and IL-6 were slightly upregulated and the expression of TGF-β was significantly upregulated in the CCl₄ injection group compared with the control group (P<0.05). In contrast, the mRNA expressions of IL-1b and IL-6 were significantly up-regulated and the expression of TGF-β decreased in the CCl₄ injection combined with atorvastatin group compared with the CCl₄ injection group (P<0.05). The expression of pSmad4 protein increased in the CCl₄ injection group compared with the control group, while the expression of pSmad4 protein was lower in the CCl₄ injection combined with atorvastatin group compared with the CCl₄ injection group.

Conclusion

·Atorvastatin may attenuate the occurrence and development of liver fibrosis via manipulating TGF-β signaling pathway.

Key words: atorvastatin, liver fibrosis, inflammation, transforming growth factor-β, signaling pathway

CLC Number:

R575.2

Nan WANG, Ye LU, Feng-jie HAO, Jun-qing WANG. Ameliorative effect of atorvastatin on hepatic fibrosis and its mechanism[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1619-1626.

Figures/Tables 8

TrendMD

References 23

1	Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins[J]. Cell, 2015, 161(1): 161-172.
2	Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171.
3	Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? [J]. J Hepatol, 2019, 70(1): 194-202.
4	Schierwagen R, Maybuchen L, Hittatiya K, et al. Statins improve NASH via inhibition of RhoA and Ras[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 311(4): G724-G733.
5	Chong LW, Hsu YC, Lee TF, et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells[J]. BMC Gastroenterol, 2015,15: 22.
6	Dold S, Laschke MW, Lavasani S, et al. Simvastatin protects against cholestasis-induced liver injury[J]. Br J Pharmacol, 2009, 156(3): 466-474.
7	Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965.
8	Hsiang JC, Wong GL, Tse YK, et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis[J]. J Hepatol, 2015, 63(5): 1190-1197.
9	Simon TG, King LY, Zheng H, et al. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C[J]. J Hepatol, 2015, 62(1): 18-23.
10	Yang YH, Chen WC, Tsan YT, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection[J]. J Hepatol, 2015, 63(5):1111-1117.
11	Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5):1160-1170 e3.
12	Huang YW, Lee CL, Yang SS, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study[J]. Am J Gastroenterol, 2016,111(7): 976-985.
13	Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J]. Gastroenterology, 2016, 150(2): 430-440.e1.
14	Simon TG, Bonilla H, Yan P, et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES[J]. Hepatology, 2016, 64(1): 47-57.
15	Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study[J]. Hepatology, 2017, 66(3): 896-907.
16	Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story[J]. Gut, 2015, 64(5): 830-841.
17	Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins[J]. Gut, 2020, 69(5): 953-962.
18	Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia[J]. Int J Cardiol, 2001, 77(2/3): 247-253.
19	Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ[J]. Nat Rev Immunol, 2014, 14(3): 181-194.
20	Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase[J]. Hepatology, 2007, 46(1): 242-253.
21	Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial[J]. Dig Liver Dis, 2015, 47(11): 957-963.
22	Zhou YY, Zhu GQ, Wang Y, et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma[J]. Oncotarget, 2016, 7(16): 21753-21762.
23	Wu LL, Hsieh MC, Chow JM, et al. Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients[J]. Medicine (Baltimore), 2016, 95(36): e4639.

No.	Author	Year	Location	Type	Time period	Patients numbers	Etiology	Outcomes of interest	Stain users	Nonusers
1	Chang	2017	Chinese Taipei	Propensity matched cohort	2000‒2013	1 350	HBV， HCV， ALD	Decompensated cirrhosis； Mortality	14%； 9%	28%； 18%
2	Huang	2016	Chinese Taipei	Propensity matched cohort	1997‒2009	13 086	HBV	Decompensated cirrhosis； Developing cirrhosis	2.6%； 0.9%	6.1%； 1.9%
3	Simon	2016	USA	Retrospective cohort	2001‒2014	9 135	HCV	Developing cirrhosis	14.0%	21.4%
4	Hsiang	2015	Chinese Hongkong	Propensity matched cohort	2000‒2012	53 513	HBV	Mortality	6.5%	14.3%
5	Mohanty	2016	USA	Propensity matched cohort	1996‒2009	2 747	HCV	Decompensated cirrhosis； Mortality	2.1%； 6.3%	3.9%； 11.1%
6	Simon	2015	USA	Retrospective cohort	2000‒2004	543	HCV	Developing cirrhosis	10%	28%
7	Yang	2015	Chinese Taipei	Propensity matched cohort	1999‒2010	84 213	HCV	Developing cirrhosis	6.0%	21.9%
8	Kumar	2014	USA	Retrospective cohort	1988‒2011	243	Mixed	Decompensated cirrhosis	30.0%	40.5%
9	Abraldes	2016	Spain	RCT	2010‒2013	147	Mixed	Mortality	9%	22%

No.	Author	Year	Location	Type	Time period	Patients numbers	Etiology	Outcomes of interest	Stain users	Nonusers
1	Chang	2017	Chinese Taipei	Propensity matched cohort	2000‒2013	1 350	HBV， HCV， ALD	Decompensated cirrhosis； Mortality	14%； 9%	28%； 18%
2	Huang	2016	Chinese Taipei	Propensity matched cohort	1997‒2009	13 086	HBV	Decompensated cirrhosis； Developing cirrhosis	2.6%； 0.9%	6.1%； 1.9%
3	Simon	2016	USA	Retrospective cohort	2001‒2014	9 135	HCV	Developing cirrhosis	14.0%	21.4%
4	Hsiang	2015	Chinese Hongkong	Propensity matched cohort	2000‒2012	53 513	HBV	Mortality	6.5%	14.3%
5	Mohanty	2016	USA	Propensity matched cohort	1996‒2009	2 747	HCV	Decompensated cirrhosis； Mortality	2.1%； 6.3%	3.9%； 11.1%
6	Simon	2015	USA	Retrospective cohort	2000‒2004	543	HCV	Developing cirrhosis	10%	28%
7	Yang	2015	Chinese Taipei	Propensity matched cohort	1999‒2010	84 213	HCV	Developing cirrhosis	6.0%	21.9%
8	Kumar	2014	USA	Retrospective cohort	1988‒2011	243	Mixed	Decompensated cirrhosis	30.0%	40.5%
9	Abraldes	2016	Spain	RCT	2010‒2013	147	Mixed	Mortality	9%	22%

[1]	Hao-jun ZHUANG, Mei-liang GUO, Wan-wen LIU, Hui DENG. Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 963-966.
[2]	Ze-nan WU, Chen ZHANG. Research advances in inflammatory mechanism of anhedonia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 241-245.
[3]	Ling-rong YI, Bo-tao TAN, Zu-xiong ZHAN, Yuan LIU, Ying YIN, Le-hua YU. Effects of wheeling-running exercise on AKT/mTOR pathway activity and motor-evoked potential in cortical neurons of mice [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(10): 1285-1289.
[4]	HU Yi1, 2, ZHOU Wei2, SONG Zhong-chen1, 2. Peripheral and central inflammatory changes in experimental periodontitis rats [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1579-1584.
[5]	CAO Li-yuan, MU Wei. Inducers and inhibitors of necroptosis and their research progress in diseases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1524-1529.
[6]	LI Jia1, 2, YUAN Shu-sheng3, CAO Xiu-ping4, WANG Xin-nan5, HUANG Jian1, 6, ZHENG Yue-hui2, 6. Research progress of ovarian function regulated by ovarian material metabolism through Hippo signaling pathway [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1536-1539.
[7]	YUAN Qing-yue, ZHUANG Ai, SONG Xue-fei, SHI Wo-dong, BI Xiao-ping. Effect of sinus inflammation on the prognosis of blowout orbital fracture [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1398-1401.
[8]	WANG Qi, ZHU Guan-ya, XIE Ting, GE Kui, NIU Yi-wen. Changes of ATP metabolism and purinergic receptors in inflammatory response stage of diabetic wound healing [J]. , 2020, 40(1): 10-.
[9]	LI Sen1, JIA Zi-heng1, WEI Xue-rui1, MA Sai1, LU Tian-cheng1, LI Ting-ting2, GU Yan-yun2. Role of bile acid on maintaining metabolic homeostasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1126-1130.
[10]	GONG Xu-hua1, ZHU Liang2, CHEN Chao3, QIAN Li-jun1. miR-214 promotes the progression of liver fibrosis by activating hepatic stellate cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(06): 776-784.
[11]	DOU Min1, 2, ZHENG Ying-xia2, HAN Li2, ZHAO Qian1. Role and mechanism of PRMT4 in genesis and progression of gastric cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(05): 609-618.
[12]	CHU Wei-wei, XU Jie-ying, LI Shang, ZHAI Jun-yu, DU Yan-zhi. Gut microbiota of polycystic ovary syndrome model rats induced with dehydroepiandrosterone [J]. , 2019, 39(9): 975-.
[13]	LU Hai-yang, ZHAO Wei-li. Role of gastrointestinal microbiota in tumorigenesis [J]. , 2019, 39(9): 1083-.
[14]	LONG Quan1, QIN Ji-ping2, LI Rong2, CHANG Juan2, JIANG Geng-ru3, ZHU Chun2, 3. Effects of hemodialysis and hemoperfusion combination treatment on maintenance hemodialysis patients [J]. , 2019, 39(8): 886-.
[15]	XIE Xiao-hua1, CHEN Ze1, LIU Cheng-bo1, YANG Yi-hui2, ZHANG Yong-jun1. Improvement of batyl alcohol on alveolarization arrest in newborn rats with bronchopulmonary dysplasia [J]. , 2019, 39(7): 714-.